Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients

NCT05411133 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastrointestinal Cancer
Cholangiocarcinoma
Liver Cancer
Colorectal Adenocarcinoma
Pancreatic Cancer
Gastric Cancer
Esophageal Adenocarcinoma
Gastroesophageal Junction
Gastrointestinal Neuroendocrine Tumors

Interventions

DRUG: Cabotamig (ARB202)

Sponsor

Arbele Pty Ltd